📊 INTI Key Takeaways
Is Inhibitor Therapeutics, Inc. (INTI) a Good Investment?
Inhibitor Therapeutics is in severe financial distress with negative stockholders' equity of -$1.3M, indicating liabilities exceed assets. The company generates zero revenue while burning $3.2M annually in operating cash flow with no clear path to profitability. With only $2.4M in cash and mounting losses, the company faces imminent solvency risk absent immediate capital injection or strategic intervention.
Inhibitor Therapeutics shows very weak fundamentals: it remains pre-revenue, generated a $3.30M net loss, and consumed $3.23M of operating cash over the latest period. Although cash of $2.38M and a 3.19x current ratio provide some near-term liquidity, negative equity, sustained losses, and a cash burn rate above current cash reserves point to fragile financial health and a likely need for external funding.
Why Buy Inhibitor Therapeutics, Inc. Stock? INTI Key Strengths
- Adequate short-term liquidity with 3.19x current ratio relative to immediate obligations
- Minimal long-term debt burden of only $36.9K reducing refinancing risk
- Cash position of $2.4M provides brief runway for operations
- Cash and equivalents of $2.38M support near-term operations
- Current and quick ratios of 3.19x indicate solid short-term liquidity on paper
- Long-term debt is minimal at $36.89K, limiting traditional balance-sheet leverage
INTI Stock Risks: Inhibitor Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$1.3M indicates technical insolvency and shareholder value erosion
- Zero revenue generation with $3.4M operating losses demonstrates business model failure
- Negative free cash flow of -$3.2M at current cash levels provides only 9 months of runway before insolvency
- No insider buying activity suggests management lacks confidence in turnaround prospects
- Pharmaceutical sector requires substantial R&D investment with no indication of product pipeline advancement
- No revenue generation, making growth quality and commercial viability unproven
- Negative stockholders equity of $1.29M signals balance-sheet weakness
- Operating cash burn of $3.23M exceeds cash on hand, raising financing risk
Key Metrics to Watch
- Cash balance depletion rate and months of runway remaining
- Revenue recognition milestones from pipeline or partnerships
- Stockholders' equity recovery trajectory and capital raising activities
- Quarterly operating cash burn versus cash balance
- Revenue emergence and progress toward reducing net losses
Inhibitor Therapeutics, Inc. (INTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.19x current ratio provides a solid financial cushion.
INTI Profit Margin, ROE & Profitability Analysis
INTI vs Healthcare Sector: How Inhibitor Therapeutics, Inc. Compares
How Inhibitor Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inhibitor Therapeutics, Inc. Stock Overvalued? INTI Valuation Analysis 2026
Based on fundamental analysis, Inhibitor Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inhibitor Therapeutics, Inc. Balance Sheet: INTI Debt, Cash & Liquidity
INTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inhibitor Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
INTI Revenue Growth, EPS Growth & YoY Performance
INTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | -$66.2K | $0.00 |
| Q2 2022 | N/A | -$66.2K | $0.00 |
| Q1 2022 | N/A | -$98.9K | N/A |
| Q3 2021 | N/A | -$66.2K | N/A |
| Q2 2021 | N/A | -$66.2K | N/A |
| Q1 2021 | N/A | -$127.8K | N/A |
| Q3 2020 | N/A | -$302.8K | N/A |
| Q2 2020 | N/A | -$314.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inhibitor Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
INTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inhibitor Therapeutics, Inc. (CIK: 0001042418)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INTI
What is the AI rating for INTI?
Inhibitor Therapeutics, Inc. (INTI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INTI's key strengths?
Claude: Adequate short-term liquidity with 3.19x current ratio relative to immediate obligations. Minimal long-term debt burden of only $36.9K reducing refinancing risk. ChatGPT: Cash and equivalents of $2.38M support near-term operations. Current and quick ratios of 3.19x indicate solid short-term liquidity on paper.
What are the risks of investing in INTI?
Claude: Negative stockholders' equity of -$1.3M indicates technical insolvency and shareholder value erosion. Zero revenue generation with $3.4M operating losses demonstrates business model failure. ChatGPT: No revenue generation, making growth quality and commercial viability unproven. Negative stockholders equity of $1.29M signals balance-sheet weakness.
What is INTI's revenue and growth?
Inhibitor Therapeutics, Inc. reported revenue of $0.0.
Does INTI pay dividends?
Inhibitor Therapeutics, Inc. does not currently pay dividends.
Where can I find INTI SEC filings?
Official SEC filings for Inhibitor Therapeutics, Inc. (CIK: 0001042418) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INTI's EPS?
Inhibitor Therapeutics, Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INTI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inhibitor Therapeutics, Inc. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INTI stock overvalued or undervalued?
Valuation metrics for INTI: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INTI stock in 2026?
Our dual AI analysis gives Inhibitor Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INTI's free cash flow?
Inhibitor Therapeutics, Inc.'s operating cash flow is $-3.2M, with capital expenditures of N/A.
How does INTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 3.19 (avg: 2).